These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36793616)

  • 1. Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses.
    van Rees JM; Wullaert L; Grüter AAJ; Derraze Y; Tanis PJ; Verheul HMW; Martens JWM; Wilting SM; Vink G; van Vugt JLA; Beije N; Verhoef C
    Front Oncol; 2023; 13():1083285. PubMed ID: 36793616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis.
    Wullaert L; van Rees JM; Martens JWM; Verheul HMW; Grünhagen DJ; Wilting SM; Verhoef C
    Cells; 2023 Oct; 12(21):. PubMed ID: 37947598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.
    O'Sullivan NJ; Temperley HC; Kyle ET; Sweeney KJ; O'Neill M; Gilham C; O'Sullivan J; O'Kane G; Mehigan B; O'Toole S; Larkin J; Gallagher D; McCormick P; Kelly ME
    Int J Colorectal Dis; 2024 May; 39(1):82. PubMed ID: 38809315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis.
    Guo K; Lu J; Lou Y; Zheng S
    Ther Adv Med Oncol; 2023; 15():17588359231177008. PubMed ID: 37256023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
    Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
    Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis.
    Guo N; Zhou Q; Chen X; Zeng B; Wu S; Zeng H; Sun F
    J Natl Cancer Cent; 2024 Mar; 4(1):63-73. PubMed ID: 39036387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review.
    Schraa SJ; van Rooijen KL; Koopman M; Vink GR; Fijneman RJA
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
    Peng Y; Mei W; Ma K; Zeng C
    Front Oncol; 2021; 11():763790. PubMed ID: 34868984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment.
    Zhou J; Mo H; Hu D; Zhao X; Zhou H; Pan J
    Cancer Med; 2023 Oct; 12(19):19794-19806. PubMed ID: 37746916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis.
    Gracie L; Pan Y; Atenafu EG; Ward DG; Teng M; Pallan L; Stevens NM; Khoja L
    Eur J Cancer; 2021 Oct; 158():191-207. PubMed ID: 34757258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis.
    Min L; Chen J; Yu M; Yang K; Liu D
    Biomarkers; 2023 Dec; 28(5):427-436. PubMed ID: 37036017
    [No Abstract]   [Full Text] [Related]  

  • 15. ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis.
    Wang D; Zhao P; Lu T; Ren J; Zhu L; Han X; Zhang G; Dong X; Ma H; Yu M; Cai H
    Open Life Sci; 2023; 18(1):20220615. PubMed ID: 37250841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis.
    Zaman FY; Subramaniam A; Afroz A; Samoon Z; Gough D; Arulananda S; Alamgeer M
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
    Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour DNA in the evolving treatment landscape of locally advanced rectal cancer: where does it fit in?
    Piercey O; Tie J
    Ther Adv Med Oncol; 2023; 15():17588359231160138. PubMed ID: 36936200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Circulating Tumour DNA in Asian Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Liu H; Yang H; Chen X
    Evid Based Complement Alternat Med; 2022; 2022():8019652. PubMed ID: 35251214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
    Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.